Distribution and antifungal susceptibility of yeasts isolates from intensive care unit patients
Language English Country United States Media print-electronic
Document type Journal Article
Grant support
Verzdrav ITMS: 262220220197
European Regional Development Fund
PubMed
28361459
DOI
10.1007/s12223-017-0525-8
PII: 10.1007/s12223-017-0525-8
Knihovny.cz E-resources
- Keywords
- Antifungal Drug, Caspofungin, Invasive Fungal Infection, Triazole, Voriconazole,
- MeSH
- Amphotericin B pharmacology MeSH
- Antifungal Agents pharmacology MeSH
- Candida classification drug effects genetics isolation & purification MeSH
- Fluconazole pharmacology MeSH
- Drug Resistance, Fungal MeSH
- Intensive Care Units statistics & numerical data MeSH
- Candidiasis microbiology MeSH
- Humans MeSH
- Microbial Sensitivity Tests MeSH
- Voriconazole pharmacology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Amphotericin B MeSH
- Antifungal Agents MeSH
- Fluconazole MeSH
- Voriconazole MeSH
Yeasts frequently colonize non-sterile sites in the body. The aim of the study was to determine distribution in clinical samples and antifungal susceptibility to five antifungals. From January 2013 through June 2015, 800 isolates were obtained from intensive care unit patients. Candida albicans (58.9%), Candida glabrata (20.4%), Candida krusei (8.6%), and Candida parapsilosis (3.6%) were the leading species. Majority of the C. albicans isolates were susceptible to the fluconazole. Elevated voriconazole minimal inhibitory concentrations (MICs) were observed in isolates exhibiting high fluconazole MICs, most frequently in C. glabrata. Isolates with echinocandins MICs suggesting reduced susceptibility were only sporadic cases with the exception of Trichosporon spp. The amphotericin B MICs were slightly higher for some C. krusei.
See more in PubMed
Antimicrob Agents Chemother. 2013 Dec;57(12):5836-42 PubMed
Antimicrob Agents Chemother. 2011 Apr;55(4):1794-7 PubMed
Clin Microbiol Infect. 2011 Mar;17 Suppl 1:1-12 PubMed
Int J Infect Dis. 2010 Nov;14(11):e954-66 PubMed
Clin Infect Dis. 2005 Nov 15;41(10):1455-60 PubMed
Antimicrob Agents Chemother. 2002 Jun;46(6):1704-13 PubMed
Diagn Microbiol Infect Dis. 2000 Jan;36(1):7-11 PubMed
Clin Microbiol Infect. 2014 Jun;20 Suppl 6:5-10 PubMed
J Intensive Care Med. 2010 Mar-Apr;25(2):78-92 PubMed
Chest. 2003 May;123(5 Suppl):500S-3S PubMed
Antimicrob Agents Chemother. 2009 Mar;53(3):1242-4 PubMed
Mycoses. 2007 Jan;50(1):52-7 PubMed
J Clin Microbiol. 2011 Dec;49(12):4158-63 PubMed
Int J Microbiol. 2012;2012:713687 PubMed
Drug Resist Updat. 2011 Jun;14(3):164-76 PubMed
Clin Infect Dis. 2008 Jan 1;46(1):120-8 PubMed
J Antimicrob Chemother. 2011 Dec;66(12):2880-6 PubMed
Intensive Care Med. 2002 Dec;28(12):1708-17 PubMed
Intensive Care Med. 2015 Jun;41(6):1077-88 PubMed
BMC Res Notes. 2010 Jan 03;3:1 PubMed
Antimicrob Agents Chemother. 2005 Feb;49(2):783-7 PubMed
Int J Antimicrob Agents. 2010 Jun;35(6):550-2 PubMed
Emerg Infect Dis. 2014 Nov;20(11):1833-40 PubMed
Ann Surg. 1994 Dec;220(6):751-8 PubMed
N Engl J Med. 1994 Nov 17;331(20):1325-30 PubMed
J Clin Microbiol. 2003 Feb;41(2):911 PubMed
Indian J Med Microbiol. 2014 Jan-Mar;32(1):44-8 PubMed
J Clin Microbiol. 1998 Sep;36(9):2586-9 PubMed
Antimicrob Agents Chemother. 2004 Nov;48(11):4441-3 PubMed
Antimicrob Agents Chemother. 2014;58(4):2438-40 PubMed
J Clin Microbiol. 1990 Dec;28(12):2733-8 PubMed
J Clin Microbiol. 2011 Feb;49(2):630-7 PubMed
Curr Opin Crit Care. 2010 Oct;16(5):445-52 PubMed
Antimicrob Agents Chemother. 2010 Aug;54(8):3149-54 PubMed
Curr Infect Dis Rep. 2006 Nov;8(6):427-33 PubMed
Am J Med. 2012 Jan;125(1 Suppl):S3-13 PubMed
J Clin Microbiol. 2006 May;44(5):1740-3 PubMed
Clin Infect Dis. 2006 Mar 15;42(6):753-7 PubMed
Crit Care Med. 2006 Mar;34(3):857-63 PubMed
J Clin Microbiol. 2007 Jan;45(1):70-5 PubMed
